About

Crimson Life Sciences is the first translation firm registered to ISO 13485 and ISO 14971. The firm has held continuous certification to ISO 9001 since 2002 and is the only translation service exclusively dedicated to the medical device industry. Crimson’s translation risk management methods are Notified Body endorsed and patent-pending. In 2005, Crimson joined the growing TransPerfect family of companies – the world’s largest privately-held language services provider.

Commencing operations in 1992, Crimson’s current President, Marc H. Miller, is also the firm’s founder. Marc received his undergraduate degree from Harvard University and graduate degree from the Scottish Business School at Stirling University.